Anti-PD-1 Therapy OK for Most with HIV.
The PD-1 inhibitor pembrolizumab poses no significant risks for patients with HIV and cancer, according to data presented at a recent meeting of the Society for Immunotherapy of Cancer. The findings suggest that patients with HIV should no longer be excluded from clinical trials testing checkpoint inhibitors and other novel therapies for cancer.